On June 10, 2020, InspireMD, Inc. (the “Company”) issued a press release announcing the publication of the results of its PARADIGM trial in the EuroIntervention journal. In that trial, 101 unselected consecutive real-life patients were treated with the Company’s CGuard™ MicroNET covered stent for carotid stenosis and were monitored for postprocedural neurologic events for a period of 12 months. The results displayed sustained protection against any such neurologic events. A copy of that press release is attached hereto as Exhibit 99.1 and is incorporated herein by reference.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.